FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 323:1393-1401 November 15, 1990 Number 20 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND. The prevention of invasive Haemophilus influenzae type b disease requires a vaccine that is effective when administered during the first six months of life. The infants of Alaska Natives are at particularly high risk of invasive H. influenzae type b disease. METHODS. To evaluate the protective efficacy of a H. influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine (polyribosylribitol phosphate-diphtheria toxoid [PRP-D]), we enrolled 2102 Alaska Native infants in a randomized, double-blind, placebo-controlled trial in which either the vaccine or a saline placebo was administered at approximately two, four, and six months of age. RESULTS. After 3969 subject-years of follow-up and 32 episodes of H. influenzae type b disease, the overall incidence of invasive disease was not reduced significantly in the vaccinated subjects (6.0 cases per 1000 patient-years), as compared with the placebo controls (9.6) or with other Alaska Native infants (6.0). After one, two, or three doses there was no significant protective efficacy with the vaccine; after three doses the efficacy was only 35 percent (95 percent confidence interval, -57 to 73). The lack of efficacy was not related to the age at onset of disease, age at immunization, type of disease, degree of Alaska Native heritage, time after immunization, or year of the study. Levels of H. influenzae type b anticapsular antibody in recipients of the vaccine became significantly higher than levels in those who received placebo only after the second and third doses. Even after the third dose, only 48 percent of the vaccinated infants had antibody levels of more than 0.1 microgram per milliliter (geometric mean titer, 0.18). Antibody responses did not vary with the level of maternally acquired antibody, degree of Alaska Native ancestry, or age at time of the first or second immunizations, but they increased with increasing age at time of the third dose (P less than 0.001). CONCLUSIONS. We found no evidence that the PRP-D vaccine provides significant protection, at least for Alaska Native infants, against invasive diseases caused by H. influenzae type b. The ineffectiveness of the vaccine paralleled its limited immunogenicity.

Source Information

Department of Pediatrics, Harbor-UCLA Medical Center.

This article has been cited by other articles:

• Singleton, R., Hammitt, L., Hennessy, T., Bulkow, L., DeByle, C., Parkinson, A., Cottle, T. E., Peters, H., Butler, J. C. (2006). The Alaska Haemophilus influenzae Type b Experience: Lessons in Controlling a Vaccine-Preventable Disease. Pediatrics 118: e421-e429 [Abstract] [Full Text]  
• Segal, S., Pollard, A. J. (2005). Vaccines against bacterial meningitis. Br Med Bull 72: 65-81 [Abstract] [Full Text]  
• Finn, A. (2004). Bacterial polysaccharide-protein conjugate vaccines. Br Med Bull 70: 1-14 [Abstract] [Full Text]  
• Peltola, H. (2000). Worldwide Haemophilus influenzae Type b Disease at the Beginning of the 21st Century: Global Analysis of the Disease Burden 25 Years after the Use of the Polysaccharide Vaccine and a Decade after the Advent of Conjugates. Clin. Microbiol. Rev. 13: 302-317 [Abstract] [Full Text]  
• Clemens, J., Brenner, R., Rao, M., Tafari, N., Lowe, C. (1996). Evaluating New Vaccines for Developing Countries: Efficacy or Effectiveness?. JAMA 275: 390-397 [Abstract]  
• Fedson, D. S., Shapiro, E. D., LaForce, F. M., Mufson, M. A., Musher, D. M., Spika, J. S., Breiman, R. F., Broome, C. V. (1994). Pneumococcal Vaccine After 15 Years of Use: Another View. Arch Intern Med 154: 2531-2535 [Abstract]  
• Peltola, H., Eskola, J., Kayhty, H., Takala, A. K., Makela, P. H. (1994). Clinical Comparison of the Haemophilus influenzae Type B Polysaccharide-Diphtheria Toxoid and the Oligosaccharide-CRM197 Protein Vaccines in Infancy. Arch Pediatr Adolesc Med 148: 620-625 [Abstract]  
• Shapiro, E. D. (1993). Infections Caused by Haemophilus influenzae Type b: The Beginning of the End?. JAMA 269: 264-266 [Abstract]  
• Clemens, J. D., Ferreccio, C., Levine, M. M., Horwitz, I., Rao, M. R., Edwards, K. M., Fritzell, B. (1992). Impact of Haemophilus influenzae Type b Polysaccharide-Tetanus Protein Conjugate Vaccine on Responses to Concurrently Administered Diphtheria-Tetanus-Pertussis Vaccine. JAMA 267: 673-678 [Abstract]  
• Braun, M., Gillam, S., Costello, A. M. d. L. (1992). Immunisation: what do parents and health visitors in Barnet know about meningitis and Haemophilus influenzae type b?. Health Education Journal 51: 176-178 [Abstract]  
• McMillan, J. A., Oski, F. A. (1991). Pediatrics. JAMA 265: 3156-3158 [Abstract]  
• Greenberg, D. P., Vadheim, C. M., Bordenave, N., Ziontz, L., Christenson, P., Waterman, S. H., Ward, J. I. (1991). Protective Efficacy of Haemophilus influenzae Type b Polysaccharide and Conjugate Vaccines in Children 18 Months of Age and Older. JAMA 265: 987-992 [Abstract]  
• (1990). CONJUGATE Hib VACCINE PROTECTS WHITE CHILDREN, BUT NOT ALASKA NATIVES. JWatch General 1990: 6-6 [Full Text]